Caladrius_Logo_March_2017.png
Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
February 12, 2021 08:15 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius_Logo_March_2017.png
Caladrius Biosciences Closes $25.0 Million Private Placement
January 25, 2021 17:05 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius_Logo_March_2017.png
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021
January 25, 2021 08:30 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius_Logo_March_2017.png
Caladrius Biosciences Announces $25.0 Million Private Placement
January 21, 2021 09:00 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius_Logo_March_2017.png
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction
January 19, 2021 08:00 ET | Caladrius Biosciences, Inc.
Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are...
Caladrius_Logo_March_2017.png
Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021
January 06, 2021 08:30 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius_Logo_March_2017.png
Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update
December 14, 2020 08:00 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius_Logo_March_2017.png
Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference
December 09, 2020 16:05 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius_Logo_March_2017.png
Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer
November 17, 2020 16:05 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius_Logo_March_2017.png
Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020
November 10, 2020 08:30 ET | Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...